These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2005-002438-37 A randomised phase III clinical trial investigating the effect of FRAGMin® Added to standard Therapy In patients with lung Cancer 2012-06-08 due-trials
Reported results 2006-002241-37 A randomised phase II/III multi-centre clinical trial of definitive chemo-radiaiton, with or without cetuximab, in carcinoma of the oesophagus 2012-08-15 due-trials
Reported results 2010-023230-22 A phase II trial to assess the safety, immunological activity of Trovax plus Pemetrexed/ Cisplatin in patients with malignant pleural mesothelioma. 2016-05-04 due-trials
Reported results 2012-000640-10 A randomised Phase II study of two pre-operative chemoradiotherapy regimes (oxaliplatin and capecitabine followed by radiotherapy with either oxaliplatin and capecitabine or paclitaxel and carboplatin... 2019-09-04 due-trials
Reported results 2012-003383-51 A randomised phase II trial of Olaparib maintenance versus placebo monotherapy in patients with non-small cell lung cancer 2019-02-22 due-trials
Exempt 2013-000898-68 A phase 1b/2 randomised placebo controlled trial of fulvestrant +/- AZD5363 in postmenopausal women with advanced breast cancer previously treated with a third generation aromatase inhibitor. not-yet-due
Other 2014-001208-23 A randomised, double blind, placebo controlled, phase II study of fulvestrant with or without the addition of vandetanib as treatment for patients with metastatic breast cancer resistant to aromatase ... not-yet-due
Other 2014-003392-32 A Phase II/III trial of risk-stratified, reduced intensity adjuvant treatment in patients undergoing transoral surgery for Human papillomavirus (HPV)-positive oropharyngeal cancer not-yet-due
Other 2015-001740-11 A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a po... not-yet-due